Markers of Increased Risk of Intracerebral Hemorrhage After Intravenous Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke in Clinical Practice
Top Cited Papers
Open Access
- 9 April 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (14) , 1679-1685
- https://doi.org/10.1161/01.cir.0000012747.53592.6a
Abstract
Background— Intravenous recombinant tissue plasminogen activator (rtPA) is an effective therapy for acute ischemic stroke, but it is associated with risk of intracerebral hemorrhage (ICH). Our aim was to identify, in a large cohort of patients, readily available baseline factors that are associated with thrombolysis-related ICH.Keywords
This publication has 8 references indexed in Scilit:
- Early stroke treatment associated with better outcomeNeurology, 2000
- Use of Tissue-Type Plasminogen Activator for Acute Ischemic StrokeJAMA, 2000
- Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute StrokeJAMA, 2000
- Treating Acute Stroke Patients With Intravenous tPAStroke, 2000
- Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter surveyNeurology, 1999
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)Published by Elsevier ,1998
- A simulation study of the number of events per variable in logistic regression analysisJournal of Clinical Epidemiology, 1996
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995